Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum

Investor webinar scheduled for August 26, 2026 at 11:00 a.m. EDT

JERUSALEM, Aug. 24, 2026 /PRNewswire/ – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) ("Scinai" or the "Company"), a biopharmaceutical company combining innovative therapeutic development with a revenue-generating contract development and manufacturing organization ("CDMO"), today provided a corporate update and reported financial results for the six months ended June 30, 2026.

Corporate Highlights

Scinai Immunotherapeutics will host an investor webinar on August 26, 2026, to discuss recent company developments, financial performance and upcoming milestones.